254
Views
5
CrossRef citations to date
0
Altmetric
Letter to the editor

Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report

, MD, PhD, , MD, , MD, , MD, PhD, , MD, PhD & , MD, PhDORCID Icon
Pages 864-867 | Received 07 Feb 2019, Accepted 02 Apr 2019, Published online: 01 Jul 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Emmett T. Cunningham, Ramana S. Moorthy & Manfred Zierhut. (2020) Immune Checkpoint Inhibitor-Induced Uveitis. Ocular Immunology and Inflammation 28:6, pages 847-849.
Read now

Articles from other publishers (4)

S. Dierse, S. Al-Naweiseh, E. Esser, V. Englmaier, N. Eter & C. R. Clemens. (2023) Pembrolizumab (Keytruda®)-assoziierte Hypotonia bulbiPembrolizumab (Keytruda®) associated ocular hypotony. Die Ophthalmologie 120:10, pages 1042-1044.
Crossref
A. Martens, P. P. Schauwvlieghe, A. Madoe, I. Casteels & S. Aspeslagh. (2023) Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. Journal of Ophthalmic Inflammation and Infection 13:1.
Crossref
Jing Yang, Yan Li, Ruotian Xie, Xiaorong Li & Xiaomin Zhang. (2020) Sympathetic ophthalmia: Report of a case series and comprehensive review of the literature. European Journal of Ophthalmology 31:6, pages 3099-3109.
Crossref
. (2020) Recurrent sympathetic-ophthalmia. Reactions Weekly 1824:1, pages 251-251.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.